品牌及策略：HIV

In This Issue...

Introduction

Valued at more than $8.1 billion across the major pharmaceutical markets (US, Europe, and Japan) in 2006, the human immunodeficiency virus (HIV) treatment market is the largest antiviral market. More than 25 years of successful innovation have lead to a crowded and increasingly competitive market that includes several dozen approved antiretroviral agents. The HIV market has traditionally been dominated by "Big Pharma," including GlaxoSmithKline, Bristol-Myers Squibb, Roche, Pfizer, and Merck; however, the emergence of Gilead as a leader in HIV demonstrates the ability of smaller, biotechnology-oriented competitors to succeed in this highly specialized market, and a number of other biotech companies will enter the market with novel antiretrovirals before 2011. HIV has been one of the most active and well-funded areas of research and development among infectious diseases, yielding a broad and highly promising pipeline including next-generation products from existing drug classes and two novel drug classes. Integrase inhibitors (Merck' s Isentress, Gilead' s elvitegravir) and CCR5 antagonists (Pfizer' s Selzentry, Schering-Plough' s vicriviroc) represent significant clinical advances and will be important market growth drivers, propelling the HIV market to reach $10.1 billion by 2011.

Questions Answered in This Report

• GlaxoSmithKline led the HIV market in 2006 with a market share of nearly 30%; however, the company' s HIV franchise is under intense pressure from Gilead, which will become the market leader. How did GlaxoSmithKline achieve its market leading position, and why are its sales now suffering? What strategies has Gilead employed to position itself to overtake GlaxoSmithKline for market dominance?
• Gilead and GlaxoSmithKline are perceived as the most influential companies in the HIV market, and are most frequently cited as top-of-mind competitors in the field in a survey of US-based infectious disease specialists. How do physicians perceive the relative strengths of companies in the HIV market? What factors are most important in determining a physician' s perception of a company?
• 2006 saw the launch of Gilead/Bristol-Myers Squibb/Merck' s Atripla, the first complete one-pill, once-daily HIV drug regimen. How has the availability of Atripla altered physicians' prescribing habits, and which competing brands will be most affected?
• The availability of numerous antiretroviral drugs provides physicians with ample choice in terms of treatment options, but infectious disease specialists continue to cite the need for new and better therapies, especially for treatment-experienced patients. What do physicians identify as the key attributes of currently marketed agents? What are the perceived advantages and/or disadvantages of current and emerging therapies?
• The HIV pipeline features a broad array of compounds and no fewer than eleven new antiretrovirals will launch for the treatment of HIV from 2006-2011, including agents from existing and novel drug classes. What products are being developed in the major competitors' pipelines and which of these agents are most highly anticipated by physicians? How will emerging drugs perform if approved for HIV treatment?

Scope

• Markets Covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.
• Competitive Analysis: Detailed discussion of major competitors including GlaxoSmithKline, Gilead, Bristol-Myers Squibb, Abbott, Roche, Boehringer Ingelheim, Pfizer, and Merck, as well as emerging competitors Tibotec (a Johnson & Johnson company), Avexa, Achillion, Pharmasset, and Schering-Plough. Included is an analysis of each company' s HIV product portfolio, strategic positioning, and development pipeline in HIV. The report features an in-depth discussion of leading brands including approval history, sales and market position, SWOT analysis, and strategy initiatives.
• Physician Perception of Key Brands: Analysis of physician perceptions of the HIV market based on a custom survey of 50 US-based infectious disease specialists. The survey is brand-focused and examines physician perceptions of key competitors, brand attributes, and uptake of emerging agents.
• Epidemiology: Total prevalent and diagnosed cases for each of the major markets are presented in an annualized forecast from 2006 to 2011.
• Market Forecast: Annualized sales forecasts for branded agents presented by region, drug class, molecule, and brand for 2006 to 2011, including the uptake of new agents.

Table of Contents

Table of Exhibits

Executive Summary

Section 1: Disease Dynamics

• Disease Background
• Patient Populations
• HIV Prevalence and Diagnosis
• Prescribers
• HIV Treatment Dynamics
  • Drug Class Competitive Analysis
  • Emerging Agents
• Reimbursement Issues

Section 2: Competitive Analysis

• Overview of Competitive Landscape
• Physician Perception of HIV Market Competitors
• Physician Perception of Key Brands in HIV
• Promotional Spending
• Messaging

GlaxoSmithKline

• HIV Product Portfolio
• Goals and Vision in HIV
• Current Positioning
• Market Strategy
• Analysis and Future Positioning
• Combivir
  • History
  • Current Positioning
  • Competitive Analysis
  • Key Brand Strategies
  • Analysis and Future Positioning
• Trizivir
  • History
  • Current Positioning
  • Competitive Analysis
  • Key Brand Strategies
  • Analysis and Future Positioning
• Epzicom
  • History
  • Current Positioning
  • Competitive Analysis
  • Key Brand Strategies
  • Analysis and Future Positioning
• Lexiva
  • History
  • Current Positioning
  • Competitive Analysis
  • Key Brand Strategies
  • Analysis and Future Positioning
• Other Marketed HIV Products
  • Epivir
  • Ziagen
  • Retrovir
  • Agenerase
• HIV Pipeline
  • GSK-364735

Gilead

• HIV Product Portfolio
• Goals and Vision in HIV
• Current Positioning
• Market Strategy
• Analysis and Future Positioning
• Truvada
  • History
  • Current Positioning
  • Competitive Analysis
  • Key Brand Strategies
  • Analysis and Future Positioning
• Atripla
  • History
  • Current Positioning
  • Competitive Analysis
  • Key Brand Strategies
  • Analysis and Future Positioning
• Viread
  • History
  • Current Positioning
  • Competitive Analysis
  • Key Brand Strategies
  • Analysis and Future Positioning
• Other Marketed HIV Products
  • Emtriva
• HIV Pipeline
  • Elvitegravir

Bristol-Myers Squibb

• HIV Product Portfolio
• Goals and Vision in HIV
• Current Positioning
• Market Strategy
• Analysis and Future Positioning
• Reyataz
  • History
  • Current Positioning
  • Competitive Analysis
  • Key Brand Strategies
  • Analysis and Future Positioning
• Sustiva
  • History
  • Current Positioning
  • Competitive Analysis
  • Key Brand Strategies
  • Analysis and Future Positioning
• Other Marketed HIV Products
  • Zerit
  • Videx

Abbott

• HIV Product Portfolio
• Goals and Vision in HIV
• Current Positioning
• Market Strategy
• Analysis and Future Positioning
• Kaletra
  • History
  • Current Positioning
  • Competitive Analysis
  • Key Brand Strategies
  • Analysis and Future Positioning
• Other HIV Products
  • Norvir

Roche

• HIV Franchise Overview
  • Current Position and Future Outlook
• Fuzeon
  • History
  • Current Positioning
  • Competitive Analysis
  • Key Brand Strategies
  • Analysis and Future Positioning
• Other Marketed HIV Products
  • Invirase
  • Viracept
  • Hivid

Boehringer Ingelheim

• HIV Franchise Overview
  • Current Position and Future Outlook
• Marketed HIV Products
  • Viramune
  • Aptivus

Pfizer

• HIV Franchise Overview
  • Current Positioning and Future Outlook
• Marketed HIV Products
  • Viracept
  • Rescriptor
• Emerging HIV Products
  • Selzentry

Merck

• HIV Franchise Overview
  • Current Positioning and Future Outlook
• Marketed HIV Products
  • Crixivan
  • Stocrin
• Emerging HIV Products
  • Isentress

Section 3: Emerging Competitors

Tibotec (Johnson & Johnson)

• HIV Product Portfolio
• Goals and Vision in HIV
• Current Positioning
• Market Strategy
• Analysis and Future Positioning
• Prezista
  • History
  • Current Positioning
  • Competitive Analysis
  • Key Brand Strategies
  • Analysis and Future Positioning
• Emerging HIV Products
  • Etravirine (TMC125)
  • Rilpivirine (TMC278)

Other Emerging Competitors

• Achillion
  • Elvucitabine
• Avexa
  • Apricitabine (AVX-754)
• Pharmasset
  • Racivir
• Schering-Plough
  • Vicriviroc

Section 4: Market Forecast

• Market Overview
  • Drug Sales by Region
  • Drug Sales by Class
• Market Forecast
  • NRTI Market
  • PI Market
  • NNRTI Market
  • EI Market
  • Integrase Inhibitor Market

Section 5: Appendix

• Acronyms and Abbreviations
• Methodology
  • Epidemiological Forecast Methodology
  • Market Forecast Methodology
  • Competitive Analysis Methodology
  • Survey Methodology

Table of Exhibits

Executive Summary

• Exhibit 1: Key Parameters of the HIV Market, 2006 and 2011
• Exhibit 2: HIV Treatment Market ($US), Major Markets, 2006-2011
• Exhibit 3: HIV Market Competitive Landscape, 2006 and 2011
• Exhibit 4: Leading Brands in the HIV Market, 2006 and 2011
• Exhibit 5: Physician Ranked "Best" Competitors in the HIV Market

Section 1: Disease Dynamics

• Exhibit 6: HIV Life Cycle
• Exhibit 7: Prevalent and Diagnosed HIV Cases, Major Markets
• Exhibit 8: Prevalent and Diagnosed HIV Cases, US
• Exhibit 9: Prevalent and Diagnosed HIV Cases, Europe
• Exhibit 10: Prevalent and Diagnosed HIV Cases, Europe, Continued
• Exhibit 11: Prevalent and Diagnosed HIV Cases, Japan
• Exhibit 12: Physician Perception of Unmet Need in HIV
• Exhibit 13: Importance of Premarketing Activities on Physician Willingness to Prescribe a New HIV Antiretroviral
• Exhibit 14: Physician Ranking of HIV Clinical Trial Endpoints
• Exhibit 15: Impact of Information Sources in HIV
• Exhibit 16: Physician Perception of Patient Information Channels
• Exhibit 17: HIV Diagnosis and Treatment Algorithm
• Exhibit 18: US DHHS Recommended ARV Regimens for the Initiation of HIV Therapy, as of October 2006
• Exhibit 19: Definition and Key Characteristics of HIV Treatment Groups
• Exhibit 20: Approved HIV Antiretrovirals as of August 2007, by Drug Class
• Exhibit 21: Emerging HIV Antiretrovirals, by Drug Class
• Exhibit 22: Impact of Emerging Agents from Existing and Novel Antiretroviral Drug Classes
• Exhibit 23: Impact of Emerging Agents on HIV Treatment

Section 2: Competitive Analysis

• Exhibit 24: Strategies for Succes in the HIV Market
• Exhibit 25: Strategies for Success in the HIV Market, Continued
• Exhibit 26: HIV Market ($US), by Company, 2006-2011
• Exhibit 27: HIV Market Competitive Position, by Company, 2006 and 2011
• Exhibit 28: Top-of-Mind Companies in the HIV Market
• Exhibit 29: Importance of Various Factors to Physician Perception of HIV Competitors
• Exhibit 30: Physician Perception of the Five Most Influential Companies in the HIV Market
• Exhibit 31: Physician Ranked "Best" Companies in the HIV Market
• Exhibit 32: Top-of-Mind Brands in HIV Treatment
• Exhibit 33: Physician Preferred NNRTIs and PIs
• Exhibit 34: Physician Preferred NRTIs
• Exhibit 35: Promotional Spending in HIV, by Company, as a Percent of Total, 2006
• Exhibit 36: Share of Voice in Direct-to-Consumer Advertising, US, 2004-2006
• Exhibit 37: Promotional Spending for HIV Therapies, by Brand, 2006
• Exhibit 38: Volume of Promotional Material Received by Physicians, by Brand
• Exhibit 39: Frequency of Patient Requests for Antiretrovirals, by Brand
• Exhibit 40: Physician Response to Marketing Messages for a Hypothetical HIV Brand
• Exhibit 41: Physician Perception of Key Brand Messages
• Exhibit 42: Summary of GSK' s HIV Product Portfolio
• Exhibit 43: Physician Perception of GSK in the HIV Market
• Exhibit 44: GSK' s HIV Franchise Revenue, by Brand, Major Markets, 2006-2010
• Exhibit 45: Timeline of Key Events in Combivir' s Development
• Exhibit 46: Physician Perception of Combivir
• Exhibit 47: Combivir Market ($US), 2006-2011
• Exhibit 48: Combivir Market ($US), by Country, 2006-2011
• Exhibit 49: Price to Treat per day ($US), Combivir, by Country, 2006
• Exhibit 50: Timeline of Key Events in Trizivir' s Development
• Exhibit 51: Select Historic Clinical Trials with Trizivir
• Exhibit 52: Ongoing Clinical Trials with Trizivir
• Exhibit 53: Trizivir Market ($US), 2006-2011
• Exhibit 54: Trizivir Market ($US), by Country, 2006-2011
• Exhibit 55: Price to Treat per Day ($US), Trizivir, by Country, 2006
• Exhibit 56: Timeline of Key Events in Epzicom' s Development
• Exhibit 57: Physician Perception of Epzicom
• Exhibit 58: Selected Historical Clinical Trials with Epzicom
• Exhibit 59: Ongoing Clinical Trials with Epzicom
• Exhibit 60: Epzicom market ($US), 2006-2011
• Exhibit 61: Epzicom market ($US), by Country, 2006-2011
• Exhibit 62: Price to Treat per Day ($US), Epzicom, by Country, 2006
• Exhibit 63: Timeline of Key Events in Lexiva' s Development
• Exhibit 64: Physician Perception of Lexiva
• Exhibit 65: Select Historic Clinical Trials with Lexiva
• Exhibit 66: Select Historic Clinical Trials with Lexiva, continued
• Exhibit 67: Ongoing Clinical Trials with Lexiva
• Exhibit 68: Lexiva Market $US), 2006-2011
• Exhibit 69: Lexiva Market ($US), by Country, 2006-2011
• Exhibit 70: Price to Treat per Day ($US), Lexiva, 2006
• Exhibit 71: Epivir Market ($US), by Country, 2006-2011
• Exhibit 72: Price to Treat per Day ($US), Epivir, 2006
• Exhibit 73: Ziagen Market ($US), by Country, 2006-2011
• Exhibit 74: Price to Treat per Day ($US), Ziagen, 2006
• Exhibit 75: Retrovir Market ($US), by Country, 2006-2011
• Exhibit 76: Price to Treat per Day ($US), Retrovir, 2006
• Exhibit 77: Agenerase Market ($US), by Country, 2006-2011
• Exhibit 78: Price to Treat per Day ($US), Agenerase, by Country, 2006
• Exhibit 79: Summary of Gilead' s HIV Product Portfolio
• Exhibit 80: Physician Perception of Gilead in the HIV Market
• Exhibit 81: Gilead' s HIV Franchise Revenue ($US), by Brand, Major Markets, 2006-2011
• Exhibit 82: Timeline of Key Events in Truvada' s Development
• Exhibit 83: Physician Perception of Truvada.
• Exhibit 84: Physician Awareness and Response to the Gilead ' 934 Trial
• Exhibit 85: Key Drivers of Choice for Switching Patients from Combivir to Truvada
• Exhibit 86: Selected Historic Clinical Trials of Truvada
• Exhibit 87: Ongoing Clinical Trials with Truvada
• Exhibit 88: Truvada Market ($US), 2006-2011
• Exhibit 89: Truvada Market ($US), by Country, 2006-2011
• Exhibit 90: Price to Treat per Day ($US), Truvada, by Country, 2006
• Exhibit 91: Total Truvada Sales (Truvada plus Atripla [$US]), 2006-2011
• Exhibit 92: Anticipated Sources of Atripla Switches
• Exhibit 93: Physician Willingness to Switch Patients from Sustiva plus Combivir to Atripla
• Exhibit 94: Physician Willingness to Switch Patients from Trizivir Monotherapy to Atripla
• Exhibit 95: Ongoing Clinical Trials with Atripla
• Exhibit 96: Atripla Market ($US), 2006-2011
• Exhibit 97: Atripla Market ($US), by Country, 2006-2011
• Exhibit 98: Price to Treat per Day ($US), Atripla, by Country, 2006
• Exhibit 99: Gilead Atripla Revenue ($US), by Country, 2006-2011
• Exhibit 100: Timeline of Key Events in Viread' s Development
• Exhibit 101: Select Historic Clinical Trials of Viread
• Exhibit 102: Viread Market ($US), 2006-2011
• Exhibit 103: Viread Market ($US), by Country, 2006-2011
• Exhibit 104: Price to Treat per Day ($US), Viread, by Country, 2006
• Exhibit 105: Emtriva Market ($US), by Country, 2006-2011
• Exhibit 106: Price to Treat per Day ($US), Emtriva, by Country, 2006
• Exhibit 107: Elvitegravir Market ($US), by Country, 2006-2011
• Exhibit 108: Price to Treat per Day ($US), elvitegravir, by Country, 2006
• Exhibit 109: Summary of BMS' s HIV Product Portfolio
• Exhibit 110: Physician Perception of BMS in the HIV Market
• Exhibit 111: BMS' HIV Franchise Revenue, by Brand, Major Markets, 2006-2010
• Exhibit 112: Timeline of Key Events in Reyataz' Development
• Exhibit 113: Physician Perception of Reyataz
• Exhibit 114: Select Historic Clinical Trials of Reyataz
• Exhibit 115: Ongoing Clinical Trials with Reyataz
• Exhibit 116: Reyataz Market ($US), 2006-2011
• Exhibit 117: Reyataz Market ($US), by Country, 2006-2011
• Exhibit 118: Price to Treat per Day ($US), Reyataz, by Country, 2006
• Exhibit 119: Timeline of Key Events in Sustiva' s Development
• Exhibit 120: Physician Perception of Sustiva
• Exhibit 121: Expected Switching of Patients from Sustiva plus Truvada to Atripla
• Exhibit 122: Select Historic Clinical Trials of Sustiva
• Exhibit 123: Ongoing Clinical Trials with Sustiva
• Exhibit 124: Sustiva Market ($US), 2006-2011
• Exhibit 125: Sustiva Market ($US), by Country, 2006-2011
• Exhibit 126: Price to Treat per Day ($US), Sustiva, 2006
• Exhibit 127: Estimated Sustiva Revenue from Atripla ($US), by Country, 2006-2011
• Exhibit 128: Sustiva Franchise Revenue ($US), by Brand, 2006-2011
• Exhibit 129: Zerit Market ($US), by Country, 2006-2011
• Exhibit 130: Price to Treat per Day ($US), Zerit, 2006
• Exhibit 131: Videx Market ($US), by Country, 2006-2011
• Exhibit 132: Price to Treat per Day ($US), Videx, 2006
• Exhibit 133: Summary of Abbott' s HIV Product Portfolio
• Exhibit 134: Physician Perception of Abbott in the HIV Market
• Exhibit 135: Abbott' s HIV Franchise Revenue, by Brand, 2006-2011
• Exhibit 136: Timeline of Key Events in Kaletra' s Development
• Exhibit 137: Physician Perception of Kaletra
• Exhibit 138: Select Historic Clinical Trials of Kaletra
• Exhibit 139: Ongoing Clinical Trials with Kaletra
• Exhibit 140: Kaletra Market ($US), 2006-2011
• Exhibit 141: Kaletra Market ($US), by Country, 2006-2011
• Exhibit 142: Price to Treat per Day ($US), Kaletra, by Country, 2006-2011
• Exhibit 143: Norvir Market ($US), by Country, 2006-2011
• Exhibit 144: Price to Treat per Day ($US), Norvir, by Country, 2006
• Exhibit 145: Summary of Roche' s HIV Product Portfolio
• Exhibit 146: Physician Perception of Roche in the HIV Market
• Exhibit 147: Roche' s HIV Franchise Revenue ($US), by Brand, 2006-2011
• Exhibit 148: Physician Preference of Add-on Therapies for the Salvage Population
• Exhibit 149: Select Historic Clinical Trials of Fuzeon
• Exhibit 150: Ongoing Clinical Trials with Fuzeon
• Exhibit 151: Ongoing Clinical Trials with Fuzeon, Continued
• Exhibit 152: Fuzeon Market ($US), 2006-2011
• Exhibit 153: Fuzeon Market ($US), by Country, 2006-2011
• Exhibit 154: Price to Treat per Day ($US), Fuzeon, by Country, 2006
• Exhibit 155: Invirase Market ($US), by Country, 2006-2011
• Exhibit 156: Price to Treat per Day ($US), Invirase, by Country, 2006
• Exhibit 157: Viracept Market ($US), by Country, 2006-2011
• Exhibit 158: Price to Treat per Day ($US), Viracept, by Country, 2006
• Exhibit 159: Summary of Boehringer Ingelheim' s HIV Product Portfolio
• Exhibit 160: Physician Perception of Boehringer Ingelheim in HIV Treatment
• Exhibit 161: Boehringer Ingelheim' s HIV Franchise Revenue ($US), by Brand, 2006-2011
• Exhibit 162: Physician Perception of Viramune
• Exhibit 163: Viramune Market ($US), by Country, 2006-2011
• Exhibit 164: Price to Treat per Day ($US), Viramune, by Country, 2006
• Exhibit 165: Aptivus Market ($US), by Country, 2006-2011
• Exhibit 166: Price to Treat per Day ($US), Aptivus, by Country, 2006
• Exhibit 167: Summary of Pfizer' s HIV Portfolio
• Exhibit 168: Physician Perception of Pfizer in the HIV Market
• Exhibit 169: Pfizer' s HIV Franchise Revenue ($US), by Brand, 2006-2011
• Exhibit 170: Rescriptor Market ($US), by Country, 2006-2011
• Exhibit 171: Price to Treat per Day ($US), Rescriptor, by Country, 2006
• Exhibit 172: Ongoing Clinical Trials with Selzentry
• Exhibit 173: Physician Willingness to Prescribe Selzentry Based on Head-to-Head Comparison with Sustiva
• Exhibit 174: Selzentry Market ($US), 2006-2011
• Exhibit 175: Selzentry Market ($US), by Country, 2006-2011
• Exhibit 176: Price to Treat per Day ($US), Selzentry, by Country
• Exhibit 177: Summary of Merck' s HIV Product Portfolio
• Exhibit 178: Physician Perception of Merck' s Position in the HIV Market
• Exhibit 179: Merck' s HIV Franchise Revenue, by Brand, Major Markets, 2006-2011
• Exhibit 180: Crixivan Market ($US), by Country, 2006-2011
• Exhibit 181: Price to Treat per Day ($US), Crixivan, 2006
• Exhibit 182: Ongoing Clinical Trials with Isentress
• Exhibit 183: Ongoing Clinical Trials with Isentress, Continued
• Exhibit 184: Physician Willingness to Prescribe Isentress to Treatment-Naive Patients Based on the Results of BENCHMRK-IT
• Exhibit 185: Physician Willingness to Switch Patients to Isentress from Kaletra Based on Results of BENCHMRK-ExPI
• Exhibit 186: Isentress Market ($US), 2006-2011
• Exhibit 187: Isentress Market ($US), by Country, 2006-2011
• Exhibit 188: Price to Treat per Day ($US), Isentress, by Country

Section 3: Emerging Competitors

• Exhibit 189: Summary of Tibotec' s HIV Product Portfolio
• Exhibit 190: Physician Perception of Tibotec in the HIV Market
• Exhibit 191: Tibotec' s HIV Franchise Revenue, by Brand, 2006-2011
• Exhibit 192: Ongoing Clinical Trials with Prezista
• Exhibit 193: Ongoing Clinical Trials with Prezista, Continued
• Exhibit 194: Prezista Market ($US), 2006-2011
• Exhibit 195: Prezista Market ($US), by Country, 2006-2011
• Exhibit 196: Price to Treat per Day ($US), Prezista, by Country, 2006
• Exhibit 197: Etravirine Market ($US), by Country, 2006-2011
• Exhibit 198: Estimated Price to Treat per Day ($US), etravirine, by Country
• Exhibit 199: Rilpivirine Market ($US), by Country, 2006-2011
• Exhibit 200: Estimated Price to Treat per Day ($US), rilpivirine, by Country
• Exhibit 201: Elvucitabine Market ($US), by Country, 2006-2011
• Exhibit 202: Estimated Price to Treat per Day ($US), elvucitabine, by Country
• Exhibit 203: Apricitabine Market ($US), by Country, 2006-2011
• Exhibit 204: Estimated Price to Treat per Day ($US), apricitabine, by Country
• Exhibit 205: Racivir Market ($US), by Country, 2006-2011
• Exhibit 206: Estimated Price to Treat per Day ($US), racivir, by Country
• Exhibit 207: Vicriviroc Market ($US), by Country, 2006-2011
• Exhibit 208: Estimate Price to Treat per Day ($US), vicriviroc, by Country

Section 4: Market Forecast

• Exhibit 209: HIV Market ($US), Major Markets, 2006-2011 (Graphical Format)
• Exhibit 210: HIV Market ($US), Major Markets, 2006-2011 (Tabular Format)
• Exhibit 211: New Product Approvals in the HIV Market, 2006-2011
• Exhibit 212: Patent Expiries in the HIV Market, 2006-2011
• Exhibit 213: HIV Market ($US), by Country, 2006-2011
• Exhibit 214: HIV Market ($US), by Drug Class, 2006-2011
• Exhibit 215: HIV Market by Drug Class as a Percent of Total, 2006 and 2011
• Exhibit 216: NRTI Market ($US), by Drug, 2006-2011
• Exhibit 217: NRTI Market ($US), by Country, 2006-2011
• Exhibit 218: NRTI Market ($US), by Brand, 2006-2011
• Exhibit 219: NRTI Market Share, by Brand, as a Percent of Total, 2006-2011
• Exhibit 220: PI Market ($US), by Drug, 2006-2011
• Exhibit 221: PI Market ($US), by Country, 2006-2011
• Exhibit 222: PI Market ($US), by Brand, 2006-2011
• Exhibit 223: PI Market Share, by Brand as a Percent of Total, 2006-2011
• Exhibit 224: NNRTI Market ($US), by Drug, 2006-2011
• Exhibit 225: NNRTI Market ($US), by Country, 2006-2011
• Exhibit 226: NNRTI Market ($US), by Brand, 2006-2011
• Exhibit 227: EI Market ($US), by Drug, 2006-2011
• Exhibit 228: EI Market ($US), by Country, 2006-2011
• Exhibit 229: EI Market ($US), by Brand, 2006-2011
• Exhibit 230: Integrase Inhibitor Market ($US), by Drug, 2006-2011
• Exhibit 231: Integrase Inhibitor Market ($US), by Country, 2006-2011
• Exhibit 232: Integrase Inhibitor Market ($US), by Brand, 2006-2011

Section 5: Appendix

• Exhibit 233: Adjusted Price to Treat per Day of lamivudine ($US), by Country, 2006-2011
• Exhibit 234: Adjusted Price to Treat per Day of saquinavir ($US), by Country, 2006-2011
• Exhibit 235: Adjust Price to Treat per Day of Retrovir ($US), by Country, 2006-2011
• Exhibit 236: Adjusted Price to Treat per Day of Videx ($US), by Country, 2006-2011
• Exhibit 237: Adjusted Price to Treat per Day ($US) of stavudine, by Country, 2006-2011
• Exhibit 238: Adjusted Price to Treat per Day ($US) of abacavir, by Country, 2006-2011
• Exhibit 239: Days of Therapy and Compliance Assumptions
• Exhibit 240: Years in Practice of Surveyed Physicians
• Exhibit 241: HIV Patients Treated per Month by Surveyed Physicians
• Exhibit 242: Geographic Distribution of Surveyed Physicians